We are live on ! Find out more
ATHE icon

Alterity Therapeutics

7 hedge funds and large institutions have $502K invested in Alterity Therapeutics in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% less funds holding

Funds holding: 11 → 7 (-4)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less capital inflows, than outflows

Capital inflows: $681 | Capital outflows: $141K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
7
Holders Change
-4
Holders Change %
-36.36%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ATHE Hedge Fund Activity: Q1 2019 in Review

7 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2019, worth a combined $502K — up 21% from $415K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ATHE and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $681. The largest seller was Susquehanna International Group, cutting an estimated $56.9K.

  • 7 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2019, down from 11 in Q4 2018.
  • Funds reported $502K of Alterity Therapeutics stock for Q1 2019, up 21% quarter-over-quarter.
  • 0 funds opened new Alterity Therapeutics positions in Q1 2019 and 5 closed out, a net change of -5 holders.
  • The largest Alterity Therapeutics buyer in Q1 2019 was Morgan Stanley, an estimated $681 added.
  • The largest Alterity Therapeutics seller in Q1 2019 was Susquehanna International Group, an estimated $56.9K sold.

Based on aggregated 13F filings for Q1 2019.